Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

The future of Cassava Sciences appears uncertain following the definitive termination of its Alzheimer’s disease program. Detailed clinical trial data has confirmed the failure of its lead drug candidate, Simufilam, dealing a significant blow to the company’s core strategy. This setback is compounded by regulatory obstacles and substantial legal costs that are hampering efforts to pivot to new initiatives.

Recently published results in the Journal of Prevention of Alzheimer’s Disease have formally corroborated the negative outcomes initially communicated in late 2024 and early 2025. The Phase 3 studies demonstrated that Simufilam did not meet its primary or secondary endpoints in patients with Alzheimer’s. While the drug Read more...